The Medicines Patent Pool (MPP) works to improve access to treatments for HIV, hepatitis C, tuberculosis and other patented essential medicines with high medical and public health value, in low- and middle-income countries.
Since our creation in 2010, we have published a list of priority treatments for our licensing programme. This started in HIV and was subsequently expanded to include hepatitis C and tuberculosis.
In 2018, following an extensive feasibility study, our mandate was expanded to include key medicines in other diseases areas that were on the WHO Model List of Essential Medicines (EML) or had strong potential for future inclusion, such as those for treating cancer, diabetes or cardiovascular diseases. In 2019, MPP started exploring the opportunity to apply its model to long-acting formulations and technologies that could be important in LMICs, at various levels of development.
The focus so far has been on small molecules. In 2021, the MPP Board expanded its mandate to include biotherapeutics that are on the WHO EML or have strong potential for future inclusion, which will be included in subsequent prioritisation reports.
By expanding access to essential medicines, MPP is committed to supporting Universal Health Coverage.
Our method for prioritising treatments, developed with the support of a broad range of experts, is based on addressing three sequential questions:
- How important is a given medicine in LMICs?
- Are there access challenges with respect to that medicine in LMICs?
- Is the medicine patented in LMICs?
The 2021 Prioritisation Report includes: three HIV and one TB compound, as well as one long-acting technology. For the first time, the report also includes essential medicines for non-communicable diseases that were identified by the WHO Expert Committee on the Selection and Use of Essential Medicines as treatments for which MPP should explore obtaining licences. This includes eight cancer medicines, one class of diabetes medicines and one compound for RNMCH.
The current target products for licensing are:
Priorities in HIV:
Priorities in TB:
- Long-acting depot based on MedinCell’s BEPO® technology for malaria vector control
Essential medicines for non-communicable diseases and reproductive, maternal, newborn and child health:
- Heat Stable Carbetocin
Comments are welcome and encouraged. Please send an email to firstname.lastname@example.org, with the subject line “Comments on the 2021 Prioritisation Report”.